Inebilizumab Biosimilar - Research Grade
Product Specifications
Background
Uses the same sequence as the therapeutic antibody Inebilizumab. Our biosimilar is not afucosylated
Product Name Alternative
B4, CVID3, Leu-12
Reactivity
Human
Target
CD19
Isotype
IgG1 κ
Sequence
https://www.imgt.org/mAb-DB/
Applications
Functional Assays
Purification Method
This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Concentration
5mg/mL
Endotoxin
<1EU/mg Determined by LAL gel clotting assay
Purity
≥95% monomer by analytical SEC, >95% by SDS Page
Buffer
ICH3002
Shipping Conditions
Blue ice
Storage Conditions
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Specificity
Detects human CD19
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Applications Notes
This biosimilar is for research use only (RUO) : it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Isotype Control
Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Anti-desmoglein-3 [5G11], Mouse IgG1, kappa](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
